In a report released today, Richard Newitter from Truist Financial reiterated a Hold rating on Inari Medical (NARI – Research Report), with a price target of $58.26. The company’s shares closed yesterday at $58.26.
According to TipRanks, Newitter is a 5-star analyst with an average return of 17.6% and a 60.26% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Nevro Corp, Inspire Medical Systems, and PROCEPT BioRobotics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inari Medical with a $75.04 average price target, which is a 28.80% upside from current levels. In a report released today, Piper Sandler also downgraded the stock to a Hold with a $55.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
NARI market cap is currently $3.36B and has a P/E ratio of -987.46.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NARI in relation to earlier this year. Most recently, in December 2023, William Hoffman, a Director at NARI bought 103,492.00 shares for a total of $43,466.64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inari Medical (NARI) Company Description:
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.
Read More on NARI:
- Inari Medical to Announce Fourth Quarter and Full Year 2023 Financial Results
- Inari Medical initiated with a Buy at Needham
- Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance
- Inari Medical sees FY24 revenue $580M-$595M, consensus $583.07M
- Inari Medical sees 2023 revenue at least $493.5M, consensus $491.37M
